The expanding cell therapy market has placed new demands on supply chain services, with their shipment requirements and competition in the logistics industry rising.
I-Mab and WuXi Biologics extend their strategic partnership for biologics process development as well as clinical and commercial manufacturing to accelerate drug development in China and abroad.
Bluebird bio opens its first wholly owned manufacturing facility to produce lentiviral vectors for the company’s investigational gene and cell therapies.
Thermo Fisher Scientific bolsters its gene therapy capabilities by acquiring Brammer Bio for $1.7bn, as the market becomes an ‘increasing focus’ for customers.
Abzena and Lipum enter agreement for the development of biologics for juvenile idiopathic arthritis, using the former’s proprietary cell line and GMP resources.
Regenerative medicine raised $13.3bn in funds during 2018 but investors question whether treatments can be manufactured consistently, according to AMR annual report.
MaxCyte announces a partnership with Kite to explore the use of flow electroporation technology to enable the non-viral cell engineering of CAR-T drug candidates.
The rapid evolution of cell and gene therapy technology is leading GE Healthcare to explore partnerships to meet increasing manufacturing demand, according to the company's enterprise solutions leader.
Biogen agrees Nightstar acquisition for $800m to take on its pipeline of AAV treatments for retinal disorders, diversifyingy its pipeline in the rare disease market.
The global cell line development market grows steadily with a predicted revenue of $7.5bn by 2024, each component of the market to see CAGR between 10-15%.
GE announced a change of plans regarding its GE Healthcare business, choosing to sell off the BioPharma business for $21.4bn rather than initiate an IPO.
The WHO establishes a multi-disciplinary committee to advise on the ethical and scientific challenges of human genome editing, as the technology’s capability and utilization grows in the industry.
Oxford Genetics and Sphere Fluidics to partner, alongside additional biopharma organizations, to develop automated systems for high-throughput gene editing in mammalian cell lines.
ICT is developing upon CAR-T cell technology to enable T-cells to persist against cancer’s attempt to program death into a patient’s defensive T-cells, which could potentially treat solid tumors.
Renaissance BioScience enters a partnership with Mitacs to test its yeast-based, RNAi production platform for biocontrol and biotherapeutics applications.
Fujifilm Diosynth announces the inception of its FDB center of excellence in bioprocessing 2.0 to extend its bioprocessing innovations with a network of researchers.
The contract market for bringing biologics through the pipeline to commercialisation is growing at a rapid clip, with a recent report suggesting a high CAGR in the sector.
GE Healthcare and G-CON have combined capabilities to offer drug developers ‘readily deployable’ manufacturing platforms for cell therapies and viral vectors.
Fujifilm has launched an upgrade to its subsidiaries manufacturing capabilities, by increasing capacity by 50% at an existing facility and building an entirely new site for cell technology.
The UK has a ‘rich and vibrant’ advanced therapeutic manufacturing sector well placed to attract companies post-Brexit, says Keith Thompson, CEO of CGTC.
Funding of £7.3m will be provided across three initiatives, with the long-term aim of providing patients with access to cell and gene therapies at a faster rate.
Lonza Pharma & Biotech established itself in Israel, with the opening of a collaborative hub aiming to advance manufacturing technology for cell and gene therapy commercialization.